Tumor size reduction (measured by computed tomography scan) and overall response (measured by positron emission tomography scan) for each of 26 evaluable patients treated with brentuximab vedotin. Nineteen patients (73%) achieved complete response. See Figure 1 in the article by Forero-Torres et al that begins on page 2798.